<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348879</url>
  </required_header>
  <id_info>
    <org_study_id>20040195</org_study_id>
    <nct_id>NCT02348879</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject</brief_title>
  <official_title>A Placebo Controlled, Randomized, Double-blind, Sequential, Rising, Single Dose Study to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous AMG 403 in Healthy Young and Older Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety of AMG 403 in healthy adult subjects. The study consists
      of a 21 day screening period followed by administration of the investigational product and up
      to 154 day evaluation period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events</measure>
    <time_frame>up to 112 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant vital signs</measure>
    <time_frame>up to 112 days</time_frame>
    <description>Vital signs to be assessed included temperature, respiratory rate, pulse rate and rhythm (regular/irregular), and blood pressure. Generally, abnormal vital signs were only reported as adverse events if they required treatment or were associated with an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant chemistry, hematology and urinalysis test results</measure>
    <time_frame>up to 112 days</time_frame>
    <description>Laboratory abnormalities were defined by laboratory normal ranges and were not reported as adverse events unless symptomatic or associated with an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinically significant ECG results</measure>
    <time_frame>up to 112 days</time_frame>
    <description>ECG abnormalities were reported as adverse events if they represented a change from baseline or if associated with symptoms or an adverse event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics profile of AMG 403 including Tmax, AUClast and Cmax</measure>
    <time_frame>up to 112 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>AMG 403</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 403 administered as subcutaneous and intravenous doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 403</intervention_name>
    <description>AMG 403 is for treatment of subjects with chronic pain</description>
    <arm_group_label>AMG 403</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>contains no active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women of non-child bearing potential,

          -  Between the ages of 18 and 55 inclusive,

          -  Body mass index from 18 to 33 kg/m2,

          -  Skin type compatible with the study assessments, and without significant skin
             allergies, pigmentary disorders, tattoos, or any active dermatologic conditions that
             might interfere with the study conduct.

        Exclusion Criteria:

          -  Prior or current history of peripheral neuropathy, paraesthesias, dysesthesias, herpes
             zoster, post-herpetic neuralgia,

          -  Evidence of any current illness such as a common cold, viral syndrome, or flu-like
             symptoms, any disturbance of the autonomic nervous system,

          -  History of Raynaud's phenomenon; Know allergy or intolerance to capsaicin or hot
             peppers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>January 28, 2015</last_update_submitted>
  <last_update_submitted_qc>January 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

